Signals generated on engagement of the T-cell antigen receptor (TCR) are critical in the regulation of T-lymphocyte function. TCR signal transduction is mediated proximally by multiple tyrosine kinases, which act in concert to activate a diverse array of signaling molecules (6, 10, 35, (55) (56) (57) 64) . Key among these downstream effectors are the enzymes phospholipase C-␥1 (PLC␥1) and the extracellular-signal-regulated kinase (Erk), both of which need to be activated in order for TCR engagement to result in T cell activation. Activated PLC␥1 catalyzes the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PI-4,5-P 2 ) to inositol-1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG). The former product regulates the levels of intracellular Ca 2ϩ , while the latter is an activator of the classical (cPKC: ␣, ␤ I , ␤ II and ␥), and novel (nPKC: ␦, ε, and ) isoforms of protein kinase C (PKC) and of Ras-GRP (25). Erk is a proline-directed serine/threonine kinase that can phosphorylate and regulate multiple downstream effectors, including p90 RSK and the transcription factor Elk-1. The nature of the intervening steps between TCR stimulation and activation of these enzymes has begun to be elucidated, but our understanding of this process remains incomplete. Considerable evidence points to a required Lck/Fyncatalyzed tyrosine phosphorylation of the CD3 and TCR chains, with the resultant TCR recruitment and activation of the protein tyrosine kinase (PTK) ZAP-70, which then phosphorylates two of its substrates, SLP-76 and LAT, on key tyrosine residues (10, 35, 56, 57, 64) . These last two proteins serve as linker molecules. They have no intrinsic enzymatic activity but, when tyrosine phosphorylated, function by appropriately colocalizing other signaling molecules. SLP-76 is cytosolic, while the majority of LAT partitions to the lipid rafts by virtue of posttranslational palmitoylation proximal to the endofacial side of its transmembrane domain. When phosphorylated, LAT binds directly to PLC␥1, Grb2, Grap, and Gads, effectively localizing these molecules and their associated proteins (including phosphatidylinositol 3-kinase, SOS, c-Cbl, Vav, SLP-76, and Itk) to the lipid rafts of the plasma membrane. This event is thought to be required for PLC␥1 tyrosine phosphorylation and activation, as well as the activation of Erk. It has been proposed that the LAT-assembled complex colocalizes PLC␥1 with the activated PTK (possibly Itk) that phosphorylates and activates it and that this process requires 56, 64) . Additionally, LAT association positions PLC␥1 near its substrate, PI-4,5-P 2 , potentially increasing the rate of PI-4,5-P 2 hydrolysis.
Signals generated on engagement of the T-cell antigen receptor (TCR) are critical in the regulation of T-lymphocyte function. TCR signal transduction is mediated proximally by multiple tyrosine kinases, which act in concert to activate a diverse array of signaling molecules (6, 10, 35, (55) (56) (57) 64) . Key among these downstream effectors are the enzymes phospholipase C-␥1 (PLC␥1) and the extracellular-signal-regulated kinase (Erk), both of which need to be activated in order for TCR engagement to result in T cell activation. Activated PLC␥1 catalyzes the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PI-4,5-P 2 ) to inositol-1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG). The former product regulates the levels of intracellular Ca 2ϩ , while the latter is an activator of the classical (cPKC: ␣, ␤ I , ␤ II and ␥), and novel (nPKC: ␦, ε, and ) isoforms of protein kinase C (PKC) and of Ras-GRP (25) . Erk is a proline-directed serine/threonine kinase that can phosphorylate and regulate multiple downstream effectors, including p90 RSK and the transcription factor Elk-1. The nature of the intervening steps between TCR stimulation and activation of these enzymes has begun to be elucidated, but our understanding of this process remains incomplete. Considerable evidence points to a required Lck/Fyncatalyzed tyrosine phosphorylation of the CD3 and TCR chains, with the resultant TCR recruitment and activation of the protein tyrosine kinase (PTK) ZAP-70, which then phosphorylates two of its substrates, SLP-76 and LAT, on key tyrosine residues (10, 35, 56, 57, 64) . These last two proteins serve as linker molecules. They have no intrinsic enzymatic activity but, when tyrosine phosphorylated, function by appropriately colocalizing other signaling molecules. SLP-76 is cytosolic, while the majority of LAT partitions to the lipid rafts by virtue of posttranslational palmitoylation proximal to the endofacial side of its transmembrane domain. When phosphorylated, LAT binds directly to PLC␥1, Grb2, Grap, and Gads, effectively localizing these molecules and their associated proteins (including phosphatidylinositol 3-kinase, SOS, c-Cbl, Vav, SLP-76, and Itk) to the lipid rafts of the plasma membrane. This event is thought to be required for PLC␥1 tyrosine phosphorylation and activation, as well as the activation of Erk. It has been proposed that the LAT-assembled complex colocalizes PLC␥1 with the activated PTK (possibly Itk) that phosphorylates and activates it and that this process requires Gadsbound SLP-76 (35, 56, 64) . Additionally, LAT association positions PLC␥1 near its substrate, PI-4,5-P 2 , potentially increasing the rate of PI-4,5-P 2 hydrolysis.
Precisely how the formation of the LAT-associated signaling complex leads to Erk activation is unclear. Erk activation proceeds primarily through the sequential activation of Ras, Raf-1, and MEK. It has been suggested that Ras is activated in TCR-stimulated T cells via recruitment of Grb2-associated SOS, a guanine nucleotide exchange factor for Ras, to the plasma membrane by virtue of the capability of the SH2 domains of Grb2 to bind to membrane-resident, tyrosine-phosphorylated proteins such as LAT (10, 35, 56, 64) . This is analogous to what has been observed for Ras activation mediated by the engagement of growth factor receptors (37) . However, other mechanisms of Ras activation have also been found in T cells. One mechanism involves activation of PKC (6) , which can activate Raf-1 directly (7, 26, 32, 53) , and another involves Ras-GRP, which is expressed at high levels in lymphocytes, and was recently identified as a phorbol ester-activated (and presumably DAG-activated) guanine nucleotide exchange factor for Ras (15, 29, 51) . Ras-GRP is required for normal thymocyte development and is activated in response to TCR engagement (14, 16) . Therefore, multiple signaling pathways probably exist for connecting TCR engagement to Ras, and subsequently Erk, activation.
Given the reported requirement for LAT and SLP-76 in TCR-initiated activation of PLC␥1 and Erk and the demonstrated importance of ZAP-70-mediated tyrosine phosphorylation in supporting the function of these linker molecules (10, 35, 56, 64) , it would be expected that ZAP-70 would also be required for PLC␥1 activation and Erk activation in TCRstimulated T cells. Indeed, a previous study found that overexpression of dominant negative forms of ZAP-70 could block the activation of nuclear factor of activated T cells (NF-AT) (an event distal to PLC␥1 and Erk activation) in Jurkat T cells (38) . In addition, it has been reported that ZAP-70-negative mutants of the Jurkat T-cell line fail to flux Ca 2ϩ or activate Erk in response to anti-CD3 monoclonal antibody (MAb) (59, 60) . However, increased Erk activation (8, 9) and Ca 2ϩ mobilization (4, 28, 47) have been measured in T-cell clones and naive CD4 ϩ peripheral T cells stimulated under partial-agonist conditions, conditions that do not support the activation of ZAP-70 (4, 28, 31, 46) . In an attempt to reconcile these apparently discrepant observations, we have reexamined the signaling pathways leading to Ca 2ϩ mobilization and Erk activation in TCR-stimulated, ZAP-70-negative P116 Jurkat T cells.
MATERIALS AND METHODS

Cells.
The wild-type E6.1 subline of Jurkat T cells (20, 41) and the P116, J14, JCaM1, and JCaM2 somatic mutants of E6.1 Jurkat, which have deficient expression of ZAP-70, SLP-76, Lck, and LAT, respectively, have been described previously (18, 49, 60, 61) . P116 cells were a gift of R.T. Abraham (Duke University, Raleigh, NC). The J14-v-29 (vector-transfected) and J14-s-11 (SLP-76-transfected) cells were a gift of A. Weiss (University of California, San Franciso, Calif.). The JCaM1 cells were purchased from the American Tissue Culture Collection, and the Lck-transfected JCaM1 cells were a gift of David B. Straus (University of Chicago, Chicago, Ill.). The JCaM2.5 and LAT-transfected JCaM2 cells (JCaM2.5B3) were a gift of A. Weiss and L. E. Samelson (National Cancer Institute, Bethesda, Md.). These cells were maintained in RPMI 1640 medium supplemented with 7.5% fetal bovine serum (HyClone), 2 mM L-glutamine, and 10 g of ciprofloxacin hydrochloride (Bayer) per ml. The parental and mutant Jurkat T-cell lines were periodically tested by flow cytometry to confirm equivalent expression levels of CD3 and by Western blotting to confirm the appropriate expression level of the signaling molecules under investigation. In particular, the P116 cells were routinely tested to ensure that ZAP-70 was not being expressed in these cells. The LG2 B lymphoblastoid cell line that expresses HLA-DR1 and B7.1 was kindly provided by A. Sette (Epimmune, San Diego, Calif.) and was maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1ϫ MEM nonessential amino acids (GIBCO), penicillin (10 IU), and streptomycin (100 g/ml) (Wisent, Montreal, Quebec, Canada).
Antibodies and other reagents. The human CD3-ε-specific MAbs OKT3 (immunoglobulin G2A [IgG 2a ]) and UCHT-1 (IgG1), were a custom ascites (Biodesign International) and purchased from Pharmingen, respectively. The MAbs to antiphosphotyrosine (4G10) and PLC␥1 were obtained from UBI. Rabbit polyclonal antibody to human phosphorylated, activated Erk was purchased from Promega or StressGen. MAb to phosphorylated, activated Erk and rabbit polyclonal antibody to phosphorylated, activated MEK were purchased from Cell Signaling. Anti-pan Ras antibody was purchased from CalBiochem. MAb (for immunoprecipitation) and rabbit antisera (for blotting) against Raf-1 were obtained from BD Transduction Laboratories and Santa Cruz Biotechnology, respectively. Horseradish peroxidase-conjugated sheep anti-mouse and donkey anti-rabbit IgGs were purchased from Amersham. Horseradish peroxidase-conjugated goat anti-rabbit IgG was from Bio-Rad. Anti-TCR V␤8-phycoarythrinP and anti-CD69-fluorescein isothiocyanate were from Pharmingen. Partially purified staphylococcal enterotoxin E (SEE) was purchased from Toxin Technologies, Inc. (Sarasota, Fla.). Purified, full-length MEK (Raf-1 substrate) was from Santa Cruz Biotechnology. The fusion protein containing the full-length sequence of Grb2 fused to the C terminus of glutathione S-transferase (GST) was purified from Escherichia coli cultures transformed with the plasmid pGEX-2TK-Grb2 (a gift of G. A. Koretzky, University of Pennsylvania, Philadelphia, Pa.) as previously described (43) . The bacterial expression plasmid encoding the Ras binding domain of Raf-1 fused to GST was a gift of S. J. Taylor (Cornell University, Ithaca, N.Y.). The NF-AT-luciferase reporter construct (36) was a gift of G. R. Crabtree.
Cellular stimulation, immunoprecipitation, affinity precipitation, and immunoblot analyses. Cells were washed and resuspended in RPMI 1640 at 10 8 cells/ml. Cell aliquots were preincubated at 37°C for 5 min prior to the addition of stimulus. OKT3 or UCHT-1 was used at the concentrations and for the durations indicated in the figures. Where indicated, the cells were also preincubated for 15 min at 37°C with the PKC inhibitors Gö6850, Gö6976, or Ro-31-8220 or the tyrosine kinase inhibitor PP-1. Inhibitors were purchased from Calbiochem. Anti-CD3 stimulation was terminated by the addition of 5 volumes of 4°C lysis buffer [20 mM HEPES (pH 7.4), 1% Triton X-100, 50 mM ␤-glycerophosphate, 2 mM EGTA, 10 mM sodium fluoride, 1 mM sodium orthovanadate, 10% glycerol, 10 g of leupeptin per ml, 10 g of aprotinin per ml, 100 g of 4-(2-aminoethyl)-benzenesulfonyl fluoride) per ml]. After a 30-min incubation on ice, whole-cell lysates (WCL) were prepared by a 10-min centrifugation at 4°C and 21,000 ϫ g. The lysates were either directly analyzed by Western blotting or subjected to immunoprecipitation or affinity precipitation with GST-Grb2 followed by immunoblotting as previously described (43) . Immunoblots were developed by enhanced chemiluminescence using the Renaissance horseradish peroxidase substrate (Dupont NEN). Where indicated, the immunoblots were quantitated by densitometric analysis using Scion Image (Scion Corp.)
Ras and Raf-1 activation assays. The Ras activation assay was carried out as previously described (50) . In brief, Jurkat lysates were incubated with a glutathione agarose-immobilized GST fusion protein containing the Ras binding domain (RBD) of Raf-1. The fusion protein does not bind to Ras-GDP but binds with high affinity to Ras-GTP. The amount of Ras detected in immunoblots of the GST-Raf-1-RBD affinity precipitations is a measure of Ras activation (GTP binding). The Raf-1 activation assay was carried out as previously described (3) and measures the ability of immunoprecipitated Raf-1 to phosphorylate purified MEK protein in an immune complex kinase assay, where Raf-1-phosphorylated MEK-1 is detected by immunoblotting with an antibody specific for phosphorylated MEK-1 (Ser-217 and Ser-221).
Intracellular free Ca 2؉ measurements. Jurkat and P116 cells were loaded with the Ca 2ϩ indicator dye, Indo-1-AM (Molecular Probes) essentially as described previously (60) , and stimulated with UCHT-1 (various concentrations), pervanadate (100 M Na 3 VO 4 , 300 M H 2 O 2 ) or Ionomycin (1 g/ml). A 2-ml volume of cells at a density of 5 ϫ 10 5 cells/ml were placed online into the mixing chamber of a FACStar Plus flow cytometer (Becton Dickinson). Baseline measurements were collected for 1 min, 50 l of 40ϫ stimulant was added, and measurement was continued for an additional 5 min. Stimulus-induced changes in the intracellular Ca 2ϩ concentration were determined over time by monitoring the fluorescence emission ratio of the Ca 2ϩ -bound versus free form of indo-1 at 405 and 495 nm, respectively; data were analyzed and plots were generated using MultiTime Kinetic software (Phoenix Flow Systems).
NF-AT reporter assay. The NF-AT luciferase reporter gene was transfected into Jurkat and P116 cells as previously described (42) . The cells were maintained overnight in complete medium before being stimulated with increasing concentrations of the anti-CD3 UCHT1 or phorbol myristate acetate PMA (50 ng/ml) for 6 hours at 37°C. After stimulation, the cells were washed twice in phosphate-buffered saline, lysed, and analyzed by the luciferase assay system (Promega) with an Autolumat LB953 luminometer (Perkin-Elmer).
Superantigen stimulation. 
RESULTS
CD3 cross-linking activates Erk and MEK-1 in the absence of ZAP-70 expression. Previously we reported that the activation of Erk in Jurkat T cells stimulated with anti-CD3 MAb does not necessarily require the PTK ZAP-70. This conclusion was drawn from the observation that Erk2 activation, after 3 min of stimulation with OKT3, was largely comparable in both ZAP-70-negative P116 cells and in the parental, ZAP-70-replete, Jurkat T-cell line (21) . This observation was unexpected, since overexpression of dominant negative ZAP-70 blocks Erk activation in Jurkat T cells (38) , and previous studies have reported that P116 cells fail to flux Ca 2ϩ or activate Erk in response to anti-CD3 MAb (59, 60) . In light of these discrepancies, we undertook to more thoroughly examine the role played by ZAP-70 in Erk activation and the mechanisms that might underlie ZAP-70-independent Erk activation in Jurkat T cells. A kinetic analysis of Erk activation, as measured by immunoblotting for the dually phosphorylated, activated forms of Erk1 and Erk2, found that Erk activation in response to CD3 cross-linking was delayed and transient in the P116 cells compared to the wild-type Jurkat cells (Fig. 1A) . In the parental Jurkat cells, Erk activation was seen as early as 30 s and persisted at high levels from 2 to 16 min. However, in P116 cells Erk activation was not seen until 2 min after stimulation and declined rapidly thereafter, approaching baseline by 8 min. Quantitation by densitometric analysis of the anti-phosphoErk immunoblots from a similar experiment with a more extensive time course more clearly illustrates the delayed and transient nature of Erk activation in P116 cells (Fig 1C) . Activation of Erk1 and Erk2 was very rapid in CD3-stimulated Jurkat T cells, with measurable increases in Erk phosphorylation as early as 5 s after stimulation (inset in Fig. 1C ). Appreciable Erk1 and Erk2 activation in CD3-stimulated P116 cells was not detected until 1 min after stimulation. Erk1 activation was very weak in P116 cells. Identical results were obtained with OKT3 and UCHT1 (anti-CD3 MAbs of IgG 2a and IgG 1 isotypes, respectively) (data not shown). Isotype-matched control MAbs had no effect on Erk activation (data not shown), indicating that Erk activation in the P116 T cells was not due to nonspecific effects of the high concentration of antibody.
In addition to examining the kinetics of Erk activation in these two cell lines, we examined the dose response for Erk activation by 3 min of stimulation with anti-CD3 MAb (UCHT1). Erk activation in the P116 cells required approximately 10-fold more UCHT1 than was required for comparable Erk activation in the parental Jurkat cells (Fig. 1B) . Notably, while 1 g of anti-CD3 MAb per ml was sufficient to induce maximal Erk activation in the parental Jurkat T cells, this concentration was completely ineffective in stimulating Erk activation in P116 cells.
Erk phosphorylation and activation proceeds via the phosphorylation and activation of MEK-1, which directly phosphorylates the regulatory threonine and tyrosine residues of Erk. MEK-1 phosphorylation in response to CD3 stimulation in parental and P116 Jurkat T cells was measured by immunoblotting WCLs with a polyclonal antibody specific for phosphorylated MEK-1 ( Fig. 1 ). In both cell lines, CD3-stimulated MEK-1 phosphorylation proceeded via a time course and dose response that was identical to Erk phosphorylation. This is consistent with Erk phosphorylation in both the ZAP-70-neg- ative and -replete Jurkat T-cell lines proceeding through the phosphorylation and activation of MEK-1 by Raf-1. Activation of Raf-1 and Ras in the absence of ZAP-70 expression. Anti-CD3 MAb-stimulated activation of Raf-1 kinase activity was measured via an immune complex kinase assay for Raf-1 purified from either parental or P116 Jurkat T cells ( Fig. 2A) . Raf-1 activation was observed in both cell lines and, as was the case for Erk and MEK-1 phosphorylation, required higher concentrations of anti-CD3 MAb to elicit activation of Raf-1 in the ZAP-70-negative P116 cells. We also examined the time course of Raf-1 activation in the parental and P116 Jurkat T cells (Fig. 2B ). In both cell lines, the time course of Raf-1 kinase activation correlated well with the time course of Erk and MEK-1 phosphorylation stimulated by anti-CD3 MAb. These data provide additional evidence that CD3-stimulated Erk activation is likely to be proceeding via Raf-1 and MEK-1 in both the ZAP-70-replete and -deficient Jurkat T cells.
The biochemical events that regulate Raf-1 activation are complex and incompletely understood (33) ; however, Ras is recognized as a common upstream regulator of Raf-1. Ras becomes activated when GTP is bound to its guanine nucleotide binding site. Once Ras is activated, a high-affinity binding site for Raf-1 is exposed, permitting Raf-1 recruitment to the plasma membrane, an event that facilitates the activation of Raf-1. To assess if Ras becomes activated on CD3 stimulation of ZAP-70-negative Jurkat T cells, increasing concentrations of anti-CD3 MAb were used to stimulate the parental and P116 Jurkat T-cell lines (Fig 3A) . The level of GTP-bound Ras was measured by its ability to coprecipitate with a GST fusion protein containing the Ras binding domain of Raf-1. Ras activation was observed in both cell lines. As with Erk and MEK phosphorylation, Ras activation was seen in the P116 cells only above 10 g of anti-CD3 MAb per ml, while much lower concentrations of anti-CD3 were effective for Ras activation in the parental Jurkat T cells. We also examined the time course of Ras activation in these two cell lines in response to stimulation with a high concentration of anti-CD3 MAb (Fig 3B) . Activated Ras could be detected as early as 2 min poststimulation and persisted to 8 min poststimulation in both cell lines. Notably, the time course for Ras activation was very similar in both the ZAP-70-negative and -replete Jurkat T-cell lines, even though activation of Raf-1, MEK-1, and Erk showed markedly delayed activation in the P116 cells. vation. In Jurkat T cells, TCR-stimulated, ZAP-70-mediated tyrosine phosphorylation of the adapter proteins SLP-76 and LAT has been correlated with efficient activation of Ras and signaling events downstream of Ras. Likewise, Jurkat T cells deficient in SLP-76 or LAT expression have been reported to be defective in these pathways (18, 61, 63) . We examined whether the high concentration of stimulatory anti-CD3 MAb used in our studies is sufficient to stimulate appreciable LAT and SLP-76 tyrosine phosphorylation in ZAP-70-negative P116 T cells. A fusion protein containing full-length Grb2 fused to GST was used to concurrently precipitate SLP-76 and LAT (5, 34, 44) from Jurkat and P116 T cells stimulated at 37°C with 10 g of UCHT1 per ml for various times between 0 and 30 min (Fig. 4A) . While tyrosine phosphorylation of SLP-76 and LAT was readily detectable within 1 min of stimulation in the parental Jurkat T cells, in the P116 cells LAT phosphorylation was undetectable and SLP-76 phosphorylation could be detected only just above background in the 2-min-stimulated sample. This suggests that Erk activation in P116 cells is occurring independently of LAT and SLP-76 tyrosine phosphorylation. Similar results were obtained in SLP-76 and LAT immunoprecipitations (data not shown).
T-cell stimulation with high concentrations of anti-CD3 MAb induces Erk activation in the absence of SLP-76 or LAT.
One would predict that if CD3-stimulated Erk activation can occur in Jurkat T-cell mutants in the absence of ZAP-70 expression and in the absence of significant LAT and SLP-76 tyrosine phosphorylation, the same CD3-stimulated Erk activation pattern should also be detectable in Jurkat T cells that fail to express LAT (JCaM2.5 cells) or SLP-76 (J14 cells). Indeed, stimulation of these cell lines with OKT3 for various times from 15s to 30 min resulted in Erk activation that was delayed and transient compared to that in cell lines in which the expression of these proteins had been restored (Figs. 4B and C).
Kinetics and dose response of PLC␥1 phosphorylation coincides with Erk activation. While there has been considerable interest in the potential of Grb2-SOS as a mediator of Ras activation, there is some evidence indicating that TCR-stimulated Ras activation may be mediated by PLC␥1 (6, 16, 25) , whose activity has been correlated with its degree of tyrosine phosphorylation (17, 39, 57) . Therefore, in consideration of the possibility that PLC␥1 activation is responsible for anti-CD3 MAb-induced activation of Erk in P116 T cells, PLC␥1 was immunoprecipitated from OKT3-stimulated P116 and Jurkat T-cell lines and the degree of tyrosine phosphorylation of PLC␥1 was measured by antiphosphotyrosine immunoblotting (Fig. 5A) . Comparable amounts of PLC␥1 were recovered in each of the immunoprecipitates. While PLC-␥1 tyrosine phosphorylation could be readily detected in Jurkat T cells after 2 min of CD3 cross-linking with as low as 1 g of UCHT1 per ml, 10 times as much UCHT1 was required to obtain a comparable level of PLC-␥1 phosphorylation in the P116 cells. Notably, the dose dependence for UCHT1 in the activation of Erk correlates well with the dose dependence for PLC␥1 tyrosine phosphorylation. Examination of the kinetics of PLC␥1 tyrosine phosphorylation after CD3 stimulation of these cells found that PLC␥1 tyrosine phosphorylation, like Erk activation, was delayed and transient in P116 cells compared to parental Jur- (Fig. 6) . dent increase in [Ca 2ϩ ] i in both cell lines, although P116 cells required substantially more MAb to initiate a response. It should be noted that the P116 data in Fig. 6A are plotted on an exaggerated scale compared to the Jurkat data in order to better visualize the Ca 2ϩ response in the P116 cells and that the stimulatory MAb dosage is 1 log unit higher in the P116 samples. Even saturating levels of anti-CD3 MAb (20 g/ml) engendered submaximal increases in [Ca 2ϩ ] i in P116 cells, taking substantially longer to reach peak values and reaching only 45% of the peak response elicited in parental Jurkat T cells stimulated with a 10-fold-lower concentration of MAb. As reported previously, pervanadate stimulation gives the same maximal response in P116 cells but is delayed in onset compared to the situation in parental Jurkat T cells (60) . Equivalent loading of Indo-1-AM into each cell line was indicated by the comparable response of both cell lines to administration of calcium ionophore (Fig 6B) . An isotype-matched control MAb had no effect on [Ca 2ϩ ] i in either cell type (data not shown). These data are consistent with the induction of a transient and weak activation of PLC␥1 in the ZAP-70-deficient P116 cells on CD3 stimulation.
Differential sensitivity of Erk activation to PKC inhibitors in anti-CD3 MAb-stimulated P116 and parental Jurkat T cells. PKC (classical and novel isoforms) is also activated in response to PLC␥1 activation. PKC has the capacity to indirectly activate Erk through its stimulatory effects on Raf-1 (7, 26, 32, 53) . Furthermore, it has been previously shown that TCR-mediated activation of the Ras/Raf-1/MEK/Erk cascade is partially sensitive to inhibition of PKC activity (6) . On the basis of the ability of CD3 stimulation of P116 cells to induce tyrosine phosphorylation of PLC␥1 and mobilization of intracellular Ca 2ϩ , we hypothesized that PLC␥1-driven PKC activation might be responsible for the Erk activation observed in these cells. To ascertain the contribution of PKC activity to Erk activation in P116 versus parental Jurkat T cells, we examined the ability of three widely used pharmacologic inhibitors of PKC to disrupt Erk activation in response to either anti-CD3 MAb cross-linking or stimulation with the phorbol ester PMA (Fig. 7) . Two of the inhibitors, Gö6850 (also known as BIM-1 or GF 109203X) and Ro-31-8220 (also known as BIM-IX), display little selectivity between the classical and novel classes of PKC isozymes, while the third inhibitor, Gö6976, is specific for the classical PKC isozymes. Looking first at PMA-stimulated Erk activation, very similar patterns were seen in P116 cells and parental Jurkat cells. Both cell lines exhibited a dosedependent loss of PMA-induced Erk activation when pretreated with the pan-PKC inhibitors Gö6850 and Ro-31-8220, while the classical-PKC-specific inhibitor Gö6976 had little effect. In contrast, CD3-stimulated Erk activation in the two cell lines showed very different susceptibilities to the inhibition of PKC activity. UCHT1-stimulated parental Jurkat cells were refractory to all but the highest doses (30 M) of Gö6850 and Ro-31-8220 used and, even then, were only partially affected. UCHT1-stimulated P116 cells, on the other hand, gave a pattern of inhibition that was nearly indistinguishable from that of PMA-stimulated Jurkat and P116 cells. Neither UCHT1-stimulated P116 nor Jurkat cells were particularly sensitive to Erk inhibition by the cPKC-specific inhibitor Gö6976 (the apparent decrement in the Erk signal in 10 and 30 M Gö6976-treated P116 cells was not a reproducible observation). These data suggest that the Erk activation observed in the CD3-stimulated ZAP-70-negative P116 cells occurs via a mechanism entirely dependent on the activation of one or more isozymes of the nPKCs, while in the ZAP-70-replete cells, PKC plays only a small role in CD3-stimulated Erk activation.
Non-Lck protein tyrosine kinase activity is required for ZAP-70-independent Erk activation. If Erk activation in P116 cells is a consequence of PLC␥1 activation subsequent to its tyrosine phosphorylation, then CD3-stimulated Erk activation in P116 cells should be subject to inhibition by PTK inhibitors. PP-1 is a potent PTK inhibitor that is selective for Src family PTKs (22) . Erk activation induced by CD3-cross-linking was inhibited in both Jurkat and P116 cells with a similar sensitivity to PP-1 (Ն30 M) (Fig. 8) . Herbimycin (a broader-specificity PTK inhibitor) (54) also blocked Erk activation comparably in FIG. 7 . Anti-CD3 MAb-stimulated Erk activation is PKC dependent in P116 cells but not in parental Jurkat T cells. Jurkat cells and P116 cells at 6 ϫ 10 7 cells/ml were preincubated for 15 min at 37°C with the indicated concentration of PKC inhibitors, prior to stimulation at 37°C with either 10 g of UCHT1 per ml for 3 min or 50 ng of PMA per ml. for 15 min. Erk activation was measured in these cells as described in the legend to As a test of whether the PTK activity required for signaling in the absence of ZAP-70 comes from Lck, we examined the Lck-negative JCaM1 cell line, which does not activate ZAP-70 in response to CD3 cross-linking (13), for its ability to support the phosphorylation of MEK and Erk in response to CD3 stimulation. UCHT1-stimulated JCaM1 cells require MAb concentrations of 10 g/ml or above to elicit detectable phosphorylation of MEK-1 and Erk; however, JCaM1 cells in which Lck expression is restored (JCaM1/Lck) respond to concentrations of UCHT1 as low as 1 g/ml (Fig. 9A) . As was seen in the ZAP-70-negative cells, the time course of Erk and MEK-1 phosphorylation is delayed in the absence of Lck expression (Fig. 9B) . In other experiments, Erk phosphorylation was also observed to be transient, although this is not evident in this experiment. These data argue that Lck is dispensable for activation of the Raf-1/MEK-1/Erk kinase cascade in response to high-concentration anti-CD3 MAb stimulation of Jurkat T cells in the absence of ZAP-70 expression (P116) or activation (JCaM1).
Failure to activate the NF-AT transcriptional reporter in CD3-stimulated P116 T cells. Given the ability of CD3 stimulation to induce Erk activation and Ca 2ϩ mobilization in ZAP-70-negative P116 T cells, we also assessed the ability of CD3 stimulation to induce transcriptional activation of the luciferase reporter construct containing the triplicated NF-AT binding sites of the interleukin-2 promoter region driving the transcription of luciferase (Fig. 10) . The parental Jurkat cells showed a dose-dependent increase in reporter activity in response to CD3 stimulation, while the P116 cells were unresponsive. The apparent increase in the constitutive level of NF-AT activity in the P116 cells is due to the relatively poor response of these cells to the 50 ng of PMA per ml used as the maximal stimulus for normalizing the results.
Superantigen induces PLC␥1 tyrosine phosphorylation, Erk activation, and CD69 upregulation in the absence of ZAP-70 expression. The high degree of TCR engagement implicit in the use of the high levels of anti-CD3 MAb is reminiscent of the conditions that can exist after challenge of peripheral T cells with superantigen (SAg). The staphylococcal enterotoxins are prototypic SAg, that stimulate T cells in a manner specific for the V␤ region of the TCR (23, 27) . SAgs have also been causally implicated in many diseases, including rheumatoid arthritis, diabetes mellitus, and toxic shock syndrome. Activation of T cells by staphylococcal enterotoxins leads to rapid proliferation followed by apoptosis or anergy. Since Jurkat cells express TCR V␣1/V␤8.1, we stimulated these cells with SEE in the context of HLA-DR1-expressing antigen-presenting cells (APCs).
APCs, LG2 B cells, pulsed with increasing amounts of SEE were used to stimulate ZAP-70-negative and -replete Jurkat T cells, and the induction of PLC␥1 tyrosine phosphorylation and Erk phosphorylation was assessed (Fig. 11A) . P116 cells did phosphorylate PLC␥1 and Erk in response to SEE-pulsed APCs, although the response was considerably weaker than that which was elicited in ZAP-70-replete Jurkat T cells at all concentrations of SEE analyzed. Analysis of the time course of PLC␥1 tyrosine phosphorylation in response to SEE-pulsed APC stimulation of the ZAP-70-negative and -replete Jurkat T-cell lines indicated that P116 and the parental Jurkat T cells exhibit markedly different kinetics (Fig. 11B, top panel) . In both cell lines, maximal phosphorylation of PLC␥1 was very rapid, being seen within 30 s. However, while PLC␥1 remained strongly tyrosine phosphorylated out to 30 min poststimulation in the parental Jurkat T cells, PLC␥1 tyrosine phosphorylation was transient in the P116 cells, falling steadily after the peak at 30 s and returning to baseline by 10 min. In contrast, the kinetics of Erk activation was comparable in the two cell lines, with rapid and prolonged phosphorylation being induced on stimulation with SEE-pulsed APCs (Fig. 11B, third panel) . As was the case throughout the study, ZAP-70 was undetectable in the P116 cells but was readily detectable in the parental Jurkat T cells.
To determine if the prolonged Erk activation that could be induced in the P116 cells in response to SEE-pulsed APC stimulation can support distal signaling events, the ability of SEE-pulsed APC stimulation to upregulate CD69 in Jurkat T cells was assessed. While SEE-pulsed APC-stimulated CD69 upregulation in P116 cells was inferior to that stimulated in ZAP-70-replete Jurkat T cells, there was nonetheless a marked increase in CD69 expression that was not seen in the absence of SEE (Fig. 12) .
DISCUSSION
Previously, in the course of experiments that examined the requirement for ZAP-70 in T cells responding to hydrogen peroxide treatment, we made the unexpected observation that although ZAP-70 was required for Erk activation in response to hydrogen peroxide, it was not necessarily required for TCRstimulated Erk activation (21) . In the present study we have attempted to determine the mechanism by which Erk becomes activated after TCR/CD3 stimulation of ZAP-70-negative Jurkat T cells by carrying out more detailed analyses of the kinetics and dose response of Erk activation in these cells, as well as by examining the status of various signaling molecules believed to be intermediate between TCR engagement and Erk activation. Additionally, to explore the potential physiologic relevance of this signaling pathway, we have examined the ability of superantigen-pulsed APCs to activate signaling in ZAP-70-negative Jurkat T cells.
In addition to confirming our previous observation of CD3-stimulated Erk activation in ZAP-70-negative Jurkat T cells, our results indicate that PLC␥1, PKC, Ras, Raf-1, and MEK-1 are being activated in these cells in response to CD3 stimulation. Notably, though, much higher concentrations of anti-CD3 MAb were required to elicit a response in the P116 T cells than were required to elicit a comparable response in the ZAP-70-replete Jurkat T cells. This finding may help to explain why previous studies with the P116 cells did not detect the activation of these signaling molecules following TCR/CD3 stimulation (59, 60) . These previous studies examined responses to only a single, comparatively low concentration of anti-CD3 MAb (1 g/ml) . In the present study, no signaling could be detected in P116 cells after stimulation with 1 g of anti-CD3 MAb per ml, even though this concentration of MAb was sufficient to induce maximal Erk activation in the parental Jurkat T cells. In addition to the requirement of P116 cells for a higher concentration of anti-CD3 MAb for induction of signaling, signaling in these cells was significantly delayed and transient compared to that in parental Jurkat T cells. This narrow kinetic window also helps to explain the failure of earlier studies to observe signaling in P116 cells in response to CD3 stimulation (59, 60) . The possibility that the P116 cell line had regained the capacity to express ZAP-70 or Syk or that the cell line had become contaminated with parental Jurkat T cells was ruled out by Western blotting for ZAP-70 and Syk (data not shown). Likewise, CD3 expression levels were equal in all cell lines (reference 24 and data not shown).
In all experiments, there was a strong positive correlation for the timing and dose dependency of phosphorylation and activation between Raf-1, MEK-1, and Erk following CD3 stimulation of both the ZAP-70-negative and -replete Jurkat T cells, although clearly the pattern of activation was different between the two cell lines. This suggests that Raf-1 and MEK-1 are intermediate signaling components between TCR/CD3 engagement and Erk activation in both cell lines and is consistent with previous reports identifying Raf-1 and MEK-1 as being upstream of TCR-stimulated Erk activation in Jurkat T cells (6) . The MEK-1 inhibitor PD98059 was also able to inhibit CD3-stimulated Erk activation in both cell lines (data not shown), further supporting this supposition.
Despite generally weaker Raf-1 and MEK-1 activation in the P116 cells, the degree of Erk2 activation, as measured by the strength of signal detected on immunoblots of dually phosphorylated Erk2 present in cellular lysates (40) , was generally comparable at the peak time point (usually 2 to 3 min poststimulation) between Jurkat and P116 cells. This presumably LG2 cell equivalents) were subjected to immunoprecipitation with anti-PLC␥-1, transferred to a polyvinylidene difluoride membrane, and immunoblotted for phosphotyrosine (top). The membrane was then stripped and blotted for PLC␥1 (middle). Lanes: APCs; PLC␥-1 immunoprecipitate from 2,000,000 LG2 cell equivalents; Beads, immunoprecipitating antibody-coated beads alone without cell lysate. WCL proteins (450,000 T-cell and 90,000 LG2 cell equivalents) were resolved by electrophoresis on 8% polyacrylamide gels, transferred to a polyvinylidene difluoride membrane, and immunoblotted for dually phosphorylated, acti- The results of the Ras activation assays with the ZAP-70-negative and -replete Jurkat T-cell lines are interesting in a number of respects. In keeping with the results for the other signaling molecules investigated, Ras was activated in the P116 cells only in response to anti-CD3 MAb in the range of 10 to 20 g/ml; however, unlike for Raf-1, MEK-1, Erk, and PLC␥1, there was no marked difference in the time course of Ras activation in the P116 cells compared to the parental Jurkat T cells. Thus, despite the failure to initiate LAT tyrosine phosphorylation in the CD3-stimulated P116 cells, Ras activation appears to be proceeding normally in these cells. Precisely how Ras is being activated under these conditions remains to be established but may involve the activation of Ras-GRP as a consequence of DAG production by activated PLC␥1 (15, 29, 51) . Additionally there is an apparent discrepancy between the time courses of Ras activation and Raf-1/MEK-1/Erk cascade activation in the CD3-stimulated P116 cells. Notably, while Ras activation peaked in both parental Jurkat and P116 cells at 30 s following stimulation with soluble anti-CD3 MAb, Erk activation was nearly maximal in wild-type Jurkat at this time whereas no Erk activation could be detected at this time in the P116 cells. While other explanations are also tenable, these results suggest the existence of additional signaling events that are required in efficiently translating Ras activation into the activation of the Raf-1, as has been suggested previously (58) . Our data suggest that ZAP-70 plays an important role in this process.
The distinct magnitude, kinetics, and dose response of Raf-1/MEK-1/Erk cascade activation in P116 cells stimulated by CD3 cross-linking compared to that in the parental Jurkat T cells suggests the existence of an alternative Raf-1 activation pathway that can be initiated in response to TCR stimulation in the absence of ZAP-70. Notably, Raf-1/MEK-1/Erk cascade activation in these cells is temporally correlated with tyrosine phosphorylation of PLC␥1 and increases in [Ca 2ϩ ] i , indicating that activation of PLC␥1, with its attendant production of IP 3 and DAG, is coincident with activation of Raf-1, MEK-1, and Erk. Unfortunately, attempts to directly test the importance of PLC␥1 in CD3-stimulated Raf-1/MEK-1/Erk cascade activation in P116 cells were uninformative, since in our hands the reported PLC␥1 pharmacologic inhibitor U73122 had no effect on PLC␥1 activity at concentrations that were not overtly toxic to the cells.
Nonetheless, the correlation between activation of the Raf-1/MEK-1/Erk cascade and PLC␥1 tyrosine phosphorylation suggests some possible mechanisms by which Erk activation may be occurring in CD3-stimulated P116 T cells. Two signaling pathways have been recognized in T cells that can support Erk activation in response to increases in the concentration of Ca 2ϩ and DAG (Fig. 13 ). The first is based on the ability of PKC to activate Raf-1 (7, 26, 32, 53) . The second pathway relies on the recently discovered guanine nucleotide exchange factor for Ras, Ras-GRP, which is believed to be activated by the binding of DAG to its C1 domain (15, 16, 51) . Support for the idea that the first pathway plays an important role in Erk activation in CD3-stimulated P116 cells is provided by the sensitivity of Erk activation in these cells to the panspecific PKC inhibitors Gö6850 and Ro-31-8220. The inability of Gö6976, a classical-PKC-selective inhibitor, to block Erk activation in P116 cells suggest that the implicated PKC is a members of the "novel" class of PKC isozymes. This result is consistent with previous results showing that transient transfection with PKC-ε (novel class) could strongly support transactivation of NF-AT and AP-1 in Jurkat T cells while PKC-␣ (classical class) was considerably less effective (19) . Which novel PKC mediates this signaling pathway remains to be established, although it is unlikely that this enzyme is PKC-, since ZAP-70 expression is required for PKC-activation in Jurkat T cells (24) and since PKC-activation requires the activation of both TCR/CD3 and CD28 (11) . Consistent with previously published results, in the ZAP-70-replete Jurkat cells, Erk activation was largely insensitive to PKC inhibition (6) . Additional studies are required to determine if Ras-GRP is also contributing to the activation of the Raf-1/MEK-1/Erk cascade in P116 cells. Although the ability of the PKC inhibitors to block Erk activation in CD3-stimulated P116 cells shows that Ras-GRP activation is not sufficient to stimulate Erk activation, DAG-mediated activation of Ras-GRP may be required for the activation of Ras observed in these cells.
Anti-CD3 MAb signaling to Erk in the P116 cells required a signal generated by an Src family PTK, as evidenced by the ability of the Src family-selective PTK inhibitor PP-1 to block Erk activation in these cells. Unlike the parental Jurkat T cells, this signal seems unlikely to be delivered by Lck in the P116 cells, since Lck does not appear to play an important role in the ZAP-70-independent activation of the Raf-1/MEK-1/Erk cascade, on the basis that Erk could also be activated following CD3 stimulation in the Lck-negative Jurkat T-cell line JCaM1, with a dose dependency and time course similar to those observed in the ZAP-70-negative P116 cells. Fyn would seem to be a logical candidate for providing the requisite Src family signal, since Fyn is also rapidly activated following TCR/CD3 stimulation (12, 52) and has been implicated in TCR/CD3-stimulated PLC␥1 activation (1, 48, 62) .
Consistent with the ability of Fyn to signal PLC␥1 and Erk activation following TCR stimulation, Denny et al. (13) have recently demonstrated that increasing the expression level of Fyn in the Lck-negative Jurkat T-cell line JCaM1 enabled signaling to multiple pathways in response to TCR/CD3 stimulation. In particular, TCR/CD3-stimulated PLC␥1 tyrosine phosphorylation, Ca 2ϩ mobilization, Ras activation, and Erk activation were all enabled, via a ZAP-70-independent signaling pathway (13) . Notably, as with the ZAP-70-negative signaling pathway that we report here, this signaling pathway was also found to be independent of LAT tyrosine phosphorylation. It seems likely that the increased expression level of Fyn in these cells has shifted the dose-response function of the signaling pathway to TCR stimulation, such that responses which previously required high levels of anti-TCR/CD3 MAb (this study) or superantigen stimulation (62) can now be stimulated with lower concentrations of soluble antibody (13). Whether increasing the expression level of Fyn in the P116 cells would permit a signaling response to lower concentrations of anti-CD3 MAb is the subject of current investigations.
In an effort to probe the physiologic relevance of a ZAP-70-independent signaling pathway that is revealed only at high levels of anti-CD3 MAb, we also tested whether SAg-pulsed APCs, which provide a potent stimulus via the TCR, could deliver activating signals to Erk in P116 cells. SEE-pulsed LG2 B cells rapidly stimulated PLC␥1 tyrosine phosphorylation and Erk activation in P116 cells, demonstrating the competency of these cells to respond to TCR stimulation via SAg. Indeed, it is interesting that Erk activation was often observed to be as good (strength of signal and duration) in SEE-stimulated P116 cells as it was in ZAP-70-replete Jurkat T cells. SEE stimulation of P116 cells also resulted in upregulation of CD69 surface expression. The differences in the duration of Erk activation and downstream signaling events (NF-AT activation or CD69 upregulation) in response to anti-CD3 MAb and SEE-pulsed LG2 B cells are likely to be due to the additional costimulatory signals provided by the APCs that are lacking during stimulation with soluble MAb to CD3, although we have not ruled out the possibility that the two stimulatory agents are activating Erk via different pathways.
In considering situations in which a mature peripheral T cell would be likely to be stimulated via TCR engagement in the absence of a signal from ZAP-70 (or Syk) activity, two scenarios seem plausible: (i) stimulation by partial-agonist-or antagonist-altered peptide ligands, and (ii) maintenance of peripheral T cell tolerance in previously tolerized T cells. It has been well established, for both T-cell clones and CD4 ϩ peripheral T cells, that engagement of the TCR with a conservatively modified major histocompatibility complex-antigenic peptide ligand or in the absence of CD4 costimulation can result in a partial engagement of the TCR-associated signaling machinery (30, 45) . A hallmark of these partial-agonist systems is that these stimuli do not activate ZAP-70, despite their ability to stimulate TCR-mediated Ca 2ϩ flux (4, 28, 47) and Erk activation (8, 9) . It seemed likely, therefore, that there should exist conditions under which the TCR of Jurkat T cells could be induced to stimulate Ca 2ϩ mobilization and Erk activation in the absence of ZAP-70 activation. This hypothesis is borne out by the data presented here. Interestingly, the increase in [Ca 2ϩ ] i that was observed in P116 cells stimulated with anti-CD3 MAb was substantially weaker than that observed in the parental Jurkat T cells, even when 100 times more stimulatory antibody was used. This is reminiscent of what has been observed for Ca 2ϩ flux in partial-agonist-stimulated cells (4, 28, 47) . Likewise, partial-agonist-stimulated Erk activation has been reported to be significantly more transient than full-agonist-stimulated Erk activation in T-cell clones (8, 9) , which is consistent with our observations in anti-CD3 MAb-stimulated P116 T cells.
The biochemical mechanism by which peripheral T cells become tolerized or anergized is incompletely understood, and even less is known about how the anergic state is maintained in these cells. It seems clear, though, that maintenance of peripheral T-cell anergy is an active process, since removal of the tolerizing antigen often results in release of anergy. On becoming anergized, T cells elevate their Fyn expression and/or activity levels three-to fourfold while simultaneously reducing the Lck expression level by 50 to 90% (2) . Anergized T cells also exhibit pronounced defects in ZAP-70 activation and show decreased SLP-76 and LAT tyrosine phosphorylation in response to TCR stimulation. Thus, anergized T cells increase their Fyn signaling capacity while simultaneously reducing their Lck signaling capacity, thereby favoring signaling pathways that bypasses ZAP-70 activation. Presumably these alterations are important in the process of initiating and maintaining tolerance in these cells. We would like to suggest that the signaling pathway that we have uncovered in the ZAP-70-negative and Lck-negative Jurkat T cells in response to highdose anti-CD3 MAb and that we and others (62) have demonstrated in these cells in response to superantigen stimulation is representative of the signaling pathway delivered by the TCR in anergized cells and may be responsible for the maintenance of anergy in these cells.
In summary, we find, contrary to previously published results, that the ZAP-70-negative Jurkat T-cell line P116 is able to generate signals in response to TCR/CD3 cross-linking that result in Ca 2ϩ mobilization and Erk activation. This finding provides further evidence for the idea that T cells can generate both ZAP-70-dependent and -independent signaling pathways. We also provide evidence to suggest that the pathways leading to Erk activation are qualitatively different in the presence and absence of ZAP-70 signaling, with the ZAP-70-independent pathway being completely dependent on PKC activation and ZAP-70-dependent Erk activation being independent of PKC activity.
